scholarly journals Natural products and other inhibitors of F1FO ATP synthase

2020 ◽  
Vol 207 ◽  
pp. 112779
Author(s):  
Bhargav A. Patel ◽  
Terin L. D’Amico ◽  
Brian S.J. Blagg
2021 ◽  
Vol 1862 (7) ◽  
pp. 148429
Author(s):  
Romero-Aguilar Lucero ◽  
Esparza-Perusquía Mercedes ◽  
Langner Thorsten ◽  
García-Cruz Giovanni ◽  
Feldbrügge Michael ◽  
...  

Life ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 242
Author(s):  
Salvatore Nesci ◽  
Fabiana Trombetti ◽  
Alessandra Pagliarani ◽  
Vittoria Ventrella ◽  
Cristina Algieri ◽  
...  

Under aerobic conditions, mitochondrial oxidative phosphorylation (OXPHOS) converts the energy released by nutrient oxidation into ATP, the currency of living organisms. The whole biochemical machinery is hosted by the inner mitochondrial membrane (mtIM) where the protonmotive force built by respiratory complexes, dynamically assembled as super-complexes, allows the F1FO-ATP synthase to make ATP from ADP + Pi. Recently mitochondria emerged not only as cell powerhouses, but also as signaling hubs by way of reactive oxygen species (ROS) production. However, when ROS removal systems and/or OXPHOS constituents are defective, the physiological ROS generation can cause ROS imbalance and oxidative stress, which in turn damages cell components. Moreover, the morphology of mitochondria rules cell fate and the formation of the mitochondrial permeability transition pore in the mtIM, which, most likely with the F1FO-ATP synthase contribution, permeabilizes mitochondria and leads to cell death. As the multiple mitochondrial functions are mutually interconnected, changes in protein composition by mutations or in supercomplex assembly and/or in membrane structures often generate a dysfunctional cascade and lead to life-incompatible diseases or severe syndromes. The known structural/functional changes in mitochondrial proteins and structures, which impact mitochondrial bioenergetics because of an impaired or defective energy transduction system, here reviewed, constitute the main biochemical damage in a variety of genetic and age-related diseases.


2020 ◽  
Vol 1861 (1) ◽  
pp. 148091 ◽  
Author(s):  
Kirill Salewskij ◽  
Bettina Rieger ◽  
Frances Hager ◽  
Tasnim Arroum ◽  
Patrick Duwe ◽  
...  

2018 ◽  
Vol 5 (4) ◽  
pp. 198-207 ◽  
Author(s):  
Nadia G Rampello ◽  
Maria Stenger ◽  
Benedikt Westermann ◽  
Heinz D Osiewacz

2010 ◽  
Vol 429 (2) ◽  
pp. 335-345 ◽  
Author(s):  
Tiffany T. Nguyen ◽  
Mourad Ogbi ◽  
Qilin Yu ◽  
John A. Johnson

The F1Fo-ATP synthase provides most of the heart's energy, yet events that alter its function during injury are poorly understood. Recently, we described a potent inhibitory effect on F1Fo-ATP synthase function mediated by the interaction of PKCδ (protein kinase Cδ) with dF1Fo (‘d’ subunit of the F1Fo-ATPase/ATP synthase). We have now developed novel peptide modulators which facilitate or inhibit the PKCδ–dF1Fo interaction. These peptides include HIV-Tat (transactivator of transcription) protein transduction and mammalian mitochondrial-targeting sequences. Pre-incubation of NCMs (neonatal cardiac myocyte) with 10 nM extracellular concentrations of the mitochondrial-targeted PKCδ–dF1Fo interaction inhibitor decreased Hx (hypoxia)-induced co-IP (co-immunoprecipitation) of PKCδ with dF1Fo by 40±9%, abolished Hx-induced inhibition of F1Fo-ATPase activity, attenuated Hx-induced losses in F1Fo-derived ATP and protected against Hx- and reperfusion-induced cell death. A scrambled-sequence (inactive) peptide, which contained HIV-Tat and mitochondrial-targeting sequences, was without effect. In contrast, the cell-permeant mitochondrial-targeted PKCδ–dF1Fo facilitator peptide, which we have shown previously to induce the PKCδ–dF1Fo co-IP, was found to inhibit F1Fo-ATPase activity to an extent similar to that caused by Hx alone. The PKCδ–dF1Fo facilitator peptide also decreased ATP levels by 72±18% under hypoxic conditions in the presence of glycolytic inhibition. None of the PKCδ–dF1Fo modulatory peptides altered the inner mitochondrial membrane potential. Our studies provide the first evidence that disruption of the PKCδ–dF1Fo interaction using cell-permeant mitochondrial-targeted peptides attenuates cardiac injury resulting from prolonged oxygen deprivation.


Author(s):  
David Spetzler ◽  
Robert Ishmukhametov ◽  
Tassilo Hornung ◽  
James Martin ◽  
Justin York ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Shui-Xiu Li ◽  
Hao-Tian Wu ◽  
Yu-Ting Liu ◽  
Yi-Ying Jiang ◽  
Yi-Shan Zhang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document